Join our daily newsletter At The Bell to receive exclusive market insights
- Respiri (RSH) has significantly enhanced the gross margins on the manufacture of its Wheezo device, with a 30 per cent improvement over previous forecasts
- The Wheezo device tracks symptoms of respiratory illnesses like asthma and can enable data sharing with health professionals
- Gross margins of 40 per cent were projected under an initial sales, distribution and logistics agreement with Cipla Australia signed in July
- Further improvements under the Entech manufacturing agreement have raised margins to 55 per cent, which is the industry standard for medical devices
- Respiri has also adjusted its agreement with Entech to pay on delivery instead of upfront, which leaves more money in Respiri’s coffers for working capital
- Respiri is trading 9.68 per cent higher for 17 cents
Respiri (RSH) has significantly enhanced the gross margins on the manufacture of its Wheezo device, with a 30 per cent improvement over previous forecasts.
The company has made significant gains in design and manufacturing efficiencies as well as a reduction in componentry which has brought down the cost of goods sold for the Wheezo version 3.0 device.
Breathing easy
The Wheezo device tracks symptoms of respiratory illnesses like asthma and can enable data sharing with health professionals to assist with patients’ health action plans.
Respiri has been steadily bringing down manufacturing costs of the device since its first batches.
Gross margins of 40 per cent were projected under an initial sales, distribution and logistics agreement with Cipla Australia signed in July.
Improvements to design, assembly and labour costs created the efficiencies, which saw an 85 per cent decrease in costs per unit compared to earlier batches.
Further enhancements have been made under the global manufacturing agreement with Entech, signed in September.
The further enhanced processes have now increased the gross margin to 55 per cent, which is largely in line with standards across the medical device industry.
Respiri has also had a material win for its working capital requirements with an adjustment to the payment terms of the Entech agreement.
Instead of paying up front, Respiri now only has to pay on delivery of the devices, meaning more capital will stay in Respiri’s hands for longer, with quicker turnaround between the outlay and recouping of funds.
Respiri CEO and Managing Director Marjan Mikel says Wheezo’s development is going according to plan, but well ahead of schedule.
“What the Respiri and Entech teams have achieved in such a short period of time has been exceptional,” Marjan said.
“These improvements have been detailed and agreed approximately 12 months ahead of plan, which is testament to our culture of continuous improvement and innovation as a company,” he added.
Outlook
With the enhanced margins, Respiri can likely expect an enhanced bottom line.
The CEO says bringing costs down so profoundly in such quick time has been testament to the company’s hard work, and will allow significantly greater flexibility going forward.
“Our lower cost of goods sold and improved product gross margins not only improves the financial performance of the business as volumes increase over time, it also affords Respiri the flexibility to adjust pricing models, if required, across different jurisdictions to reflect different demographics and capability to pay,” Marjan said.
“This will be particularly important in Asian territories over time. Having a world-class team capable of achieving these remarkable cost savings is a huge asset for Respiri now and moving into the future,” he concluded.
Respiri is trading 9.68 per cent higher for 17 cents at 1:29pm AEDT.
